Effect of G17DT in Patients With Stage II/III Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 30, 2000

Primary Completion Date

February 28, 2001

Study Completion Date

February 28, 2001

Conditions
Colorectal Cancer
Interventions
BIOLOGICAL

G17DT

G17DT is a therapeutic immunogen, formulated as a white, sterile, semi-viscous, water-in-oil emulsion (30:70 weight for weight). It was manufactured and supplied by Nova Laboratories Ltd., in glass ampoules containing 0.5 mL at a concentration of 1.25 mg/mL, as a single dose to be administered by intramuscular injection.

DRUG

Omeprazole

Proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome.

Sponsors
All Listed Sponsors
lead

Cancer Advances Inc.

INDUSTRY

NCT02518373 - Effect of G17DT in Patients With Stage II/III Colorectal Cancer | Biotech Hunter | Biotech Hunter